[Reflections on the current state of diagnosis and treatment for peritoneal metastasis in colorectal cancer].

Peritoneal metastasis of colorectal cancer is the second most common metastatic pattern after liver metastasis, clinically common and associated with a poor prognosis. Refractory subtypes such as mucinous adenocarcinoma, signet-ring cell carcinoma, and BRAF V600E-mutated colorectal cancers account for a relatively high proportion in peritoneal metastasis. While previous diagnosis and treatment faced significant challenges, recent advances in new technologies and evolving therapeutic concepts have achieved progress in management. Many patients with colorectal cancer peritoneal metastasis have obtained favorable treatment outcomes, though numerous challenges persist. This article provides an in-depth analysis of current status and advancements in the diagnosis and treatment of colorectal cancer peritoneal metastasis, examines existing clinical difficulties and unresolved issues, and explores the application of advanced technologies in clinical practice. Through promoting individualized, precise, and standardized treatment concepts, we aim to enhance survival benefits for more patients.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2025-05-25
DOI
https://doi.org/10.3760/cma.j.cn441530-20250308-00090
Primary Topic
Intraperitoneal and Appendiceal Malignancies
Type
article
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

[Reflections on the current state of diagnosis and treatment for peritoneal metastasis in colorectal cancer].

Lifang Sun, Yanjie Hu, Kefeng Ding, Jie Wang et al.
PubMed
Intraperitoneal and Appendiceal Malignancies
article

[Reflections on the current state of diagnosis and treatment for peritoneal metastasis in colorectal cancer].

Lifang Sun, Yanjie Hu, Kefeng Ding, Jie Wang, Xiangui He
article en

Abstract

Peritoneal metastasis of colorectal cancer is the second most common metastatic pattern after liver metastasis, clinically common and associated with a poor prognosis. Refractory subtypes such as mucinous adenocarcinoma, signet-ring cell carcinoma, and BRAF V600E-mutated colorectal cancers account for a relatively high proportion in peritoneal metastasis. While previous diagnosis and treatment faced significant challenges, recent advances in new technologies and evolving therapeutic concepts have achieved progress in management. Many patients with colorectal cancer peritoneal metastasis have obtained favorable treatment outcomes, though numerous challenges persist. This article provides an in-depth analysis of current status and advancements in the diagnosis and treatment of colorectal cancer peritoneal metastasis, examines existing clinical difficulties and unresolved issues, and explores the application of advanced technologies in clinical practice. Through promoting individualized, precise, and standardized treatment concepts, we aim to enhance survival benefits for more patients.

PubMedVol. 28(5)
Ministry of Education (ET)
Intraperitoneal and Appendiceal Malignancies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

[Reflections on the current state of diagnosis and treatment for peritoneal metastasis in colorectal cancer]. — Lifang Sun, Yanjie Hu, et al. · PubMed (2025) | TGRS Research Map | TGRS